Table 4.
Number of events and costs per event per patient in a cohort of 1000 patients with cancer (2019, euros)
| Rivaroxaban | Dalteparin | Incremental | ||||
| No of events | Costs per patient | No of events | Costs per patient | No of events | Costs per patient | |
| Base case (5-year time horizon) | ||||||
| Event costs | ||||||
| Recurrent VTE | 191 | €311.85 | 275 | €442.92 | −84 | −€131 |
| Non-fatal symptomatic recurrent PE | 33 | €168.36 | 48 | €239.13 | −15 | −€71 |
| Non-fatal incidental recurrent PE | 58 | – | 84 | – | −26 | |
| Non-fatal recurrent DVT | 83 | €59.31 | 120 | €84.23 | −37 | −€25 |
| Fatal recurrent VTE | 17 | €84.18 | 24 | €119.56 | −7 | −€35 |
| ICH | 11 | €550.70 | 9 | €438.40 | 2 | €112 |
| Non-ICH MB | 98 | €1106.87 | 79 | €902.47 | 19 | €204 |
| Fatal MB | 5 | €51.48 | 4 | €41.98 | 1 | €10 |
| CRNMB | 197 | €56.28 | 92 | €26.93 | 105 | €29 |
| PTS | 61 | €92.72 | 61 | €92.37 | 0 | €0 |
| CTEPH | 20 | €223.79 | 20 | €222.83 | 0 | €1 |
| Total event costs | €2705.54 | €2610.83 | €95 | |||
| Treatment costs | €548.83 | €2270.33 | −€1721 | |||
| Indirect costs | €196.31 | €177.08 | €19 | |||
| Scenario 1 (6-month time horizon) | ||||||
| Event costs | ||||||
| Recurrent VTE | 38 | €58.95 | 109 | €166.96 | −70 | −€108 |
| Non-fatal symptomatic recurrent PE | 7 | €31.82 | 19 | €90.14 | −12 | −€58 |
| Non-fatal incidental recurrent PE | 12 | – | 33 | – | −21 | – |
| Non-fatal recurrent DVT | 17 | €11.21 | 47 | €31.75 | −31 | −€21 |
| Fatal recurrent VTE | 3 | €15.91 | 9 | €45.07 | -6 | −€29 |
| ICH | 6 | €142.82 | 4 | €94.25 | 2 | €49 |
| Non-ICH MB | 50 | €539.38 | 33 | €355.95 | 17 | €183 |
| Fatal MB | 2 | €25.09 | 2 | €16.56 | 1 | €9 |
| CRNMB | 130 | €35.99 | 38 | €10.62 | 91 | €25 |
| PTS | 14 | €20.59 | 14 | €20.56 | 0 | €0 |
| CTEPH | 3 | €21.96 | 3 | €21.93 | 0 | €0 |
| Total event costs | €903.72 | €2639.25 | −€1736 | |||
| Treatment costs | €479.40 | €1947.45 | −€1468 | |||
| Indirect costs | €36.50 | €38.39 | −€2 | |||
CRNMB, clinically relevant non-major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; ICH, intracranial haemorrhage; MB, major bleeding; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VTE, venous thromboembolism.